Back to search results

Studying Islet GLP-1 in Prediabetes

This study is looking into how a natural substance called GLP-1, found in your pancreas, affects prediabetes. Researchers want to understand if problems with this GLP-1 contribute to prediabetes. You might be eligible if you are between 25 and 70 years old, have a stable weight, no history of diabetes, and specific blood sugar levels (fasting glucose below 126 mg/dL and 2-hour glucose after a sugar drink below 200 mg/dL). The study will use two interventions: Exendin 9-39, which blocks the GLP-1 receptor, and Saline (salt water). The main goal is to see how these interventions affect how well your alpha-cells and beta-cells (cells in the pancreas that make hormones) respond to sugar over a 4-hour period. The current recruitment status is unclear, and they plan to enroll 60 participants.

Study design
This is an interventional study planning to enroll 60 participants. It will compare the effects of Exendin 9-39 and Saline.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 0-240 minutes to measure alpha-cell and beta-cell responsivity to glucose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06967558

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Recruiting
PHASE2Ages 25–70InterventionalBasic science
Mayo Clinic
~60 participants
Updated 2025-12-15 on ClinicalTrials.gov
What's tested:Exendin 9-39Saline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Alpha-cell responsivity to glucose as measured by G50
Measured over 0-240 minutes
+1 more outcome measured

Conditions

PreDiabetes

Explore related trials

Glucose IntoleranceImpaired fasting glycemiaPrediabetes

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Adrian Vella, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Adrian Vella, MD
[email protected]
507-255-6515
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

People with stable weight and no history of diabetes.
Fasting glucose \< 126 mg/dL
2hr glucose after 75g OGTT \< 200 mg/dL

Exclusion

Age \< 25 or \> 70 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
HbA1c \> 6.5%
Use of any glucose-lowering agents including metformin or sulfonylureas.
For female subjects: positive pregnancy test at the time of enrollment or study
History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
Active systemic illness or malignancy.
Symptomatic macrovascular or microvascular disease.

What this trial measures

  • Alpha-cell responsivity to glucose as measured by G500-240 minutes

    The change in glucose necessary to suppress glucagon secretion by 50%

  • Beta-cell responsivity to glucose0-240 minutes

    This is measured as the gradient of the increase in insulin secretion rate per unit increase in glucose concentration